{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:56:58Z","timestamp":1768525018401,"version":"3.49.0"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.msard.2021.103308","type":"journal-article","created":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T05:46:45Z","timestamp":1633499205000},"page":"103308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Prescribing of disease modifying agents in older adults with multiple sclerosis"],"prefix":"10.1016","volume":"57","author":[{"given":"Ashna","family":"Talwar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagadeswara R.","family":"Earla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George J.","family":"Hutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajender R.","family":"Aparasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.msard.2021.103308_bib0045","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1177\/1352458511403025","article-title":"Multiple sclerosis in Hispanics: a study of clinical disease expression","volume":"17","author":"Amezcua","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103308_bib0018","unstructured":"Anon, 2021. Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS). https:\/\/ClinicalTrials.gov\/show\/NCT03073603."},{"issue":"4","key":"10.1016\/j.msard.2021.103308_bib0046","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/1352458520923945","article-title":"Frailty in ageing persons with multiple sclerosis","volume":"27","author":"Ayrignac","year":"2021","journal-title":"Mult. Scler."},{"issue":"20","key":"10.1016\/j.msard.2021.103308_bib0063","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2021.103308_bib0041","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/AOG.0000000000000541","article-title":"Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review","volume":"124","author":"Bove","year":"2014","journal-title":"Obstet. Gynecol."},{"issue":"6","key":"10.1016\/j.msard.2021.103308_bib0010","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/JNN.0000000000000172","article-title":"The elderly person with multiple sclerosis: clinical implications for the increasing life-span","volume":"47","author":"Buhse","year":"2015","journal-title":"J. Neurosci. Nurs."},{"issue":"5","key":"10.1016\/j.msard.2021.103308_bib0057","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"9856","key":"10.1016\/j.msard.2021.103308_bib0055","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"9856","key":"10.1016\/j.msard.2021.103308_bib0056","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"issue":"Pt 3","key":"10.1016\/j.msard.2021.103308_bib0003","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/brain\/awl007","article-title":"Natural history of multiple sclerosis: a unifying concept","volume":"129","author":"Confavreux","year":"2006","journal-title":"Brain"},{"issue":"20","key":"10.1016\/j.msard.2021.103308_bib0038","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM200011163432001","article-title":"Relapses and progression of disability in multiple sclerosis","volume":"343","author":"Confavreux","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2021.103308_bib0047","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00415-017-8676-8","article-title":"Changes in disability in people with multiple sclerosis: a 10-year prospective study","volume":"265","author":"Conradsson","year":"2018","journal-title":"J. Neurol."},{"issue":"13","key":"10.1016\/j.msard.2021.103308_bib0061","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1177\/1352458518800815","article-title":"Age is a critical determinant in recovery from multiple sclerosis relapses","volume":"25","author":"Conway","year":"2019","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2021.103308_bib0037","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/1352458511417479","article-title":"Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis","volume":"18","author":"Cossburn","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103308_bib0035","unstructured":"Costello, K., et\u00a0al., The use of disease-modifying therapies in multiple sclerosis, principles and current evidence\u2013a consensus paper by the Multiple Sclerosis Coalition. 2019."},{"issue":"2","key":"10.1016\/j.msard.2021.103308_bib0043","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1001\/archneurol.2008.541","article-title":"Modification of multiple sclerosis phenotypes by African ancestry at HLA","volume":"66","author":"Cree","year":"2009","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2021.103308_bib0029","first-page":"113","article-title":"Utilization patterns of oral disease-modifying drugs in commercially insured patients with multiple sclerosis","volume":"25","author":"Desai","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"2","key":"10.1016\/j.msard.2021.103308_bib0007","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1037\/0090-5550.49.2.123","article-title":"A comparison of older and younger individuals with multiple sclerosis: A preliminary investigation","volume":"49","author":"DiLorenzo","year":"2004","journal-title":"Rehabilitation Psychology"},{"key":"10.1016\/j.msard.2021.103308_bib0019","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.2147\/PPA.S270557","article-title":"Comparative adherence trajectories of oral fingolimod and injectable disease modifying agents in multiple sclerosis","volume":"14","author":"Earla","year":"2020","journal-title":"Patient Prefer. Adher."},{"issue":"6","key":"10.1016\/j.msard.2021.103308_bib0020","first-page":"741","article-title":"Marginal health care expenditure burden among U.S. civilian noninstitutionalized individuals with multiple sclerosis: 2010-2015","volume":"26","author":"Earla","year":"2020","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"12","key":"10.1016\/j.msard.2021.103308_bib0021","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.sapharm.2020.02.016","article-title":"Use of disease modifying agents in patients with multiple sclerosis: analysis of ten years of national data","volume":"16","author":"Earla","year":"2020","journal-title":"Res. Soc. Adm. Pharm."},{"key":"10.1016\/j.msard.2021.103308_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102334","article-title":"Factors associated with prescribing oral disease modifying agents in multiple sclerosis: a real-world analysis of electronic medical records","volume":"45","author":"Earla","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2021.103308_bib0059","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.msard.2016.06.001","article-title":"Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: systematic review and network meta-analysis","volume":"9","author":"Fogarty","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"12","key":"10.1016\/j.msard.2021.103308_bib0058","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","article-title":"Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis","volume":"367","author":"Fox","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.103308_bib0048","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jns.2016.02.025","article-title":"Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients","volume":"363","author":"Fox","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2021.103308_bib0062","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2147\/NDT.S147874","article-title":"New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab","volume":"14","author":"Frau","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"3","key":"10.1016\/j.msard.2021.103308_bib0052","first-page":"715","article-title":"Monitoring, switching, and stopping multiple sclerosis disease-modifying therapies","volume":"25","author":"Gross","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"issue":"3","key":"10.1016\/j.msard.2021.103308_bib0051","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.msard.2021.103308_bib0031","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1177\/1352458518765656","article-title":"Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60","volume":"25","author":"Hua","year":"2019","journal-title":"Mult. Scler."},{"issue":"1 Suppl 1","key":"10.1016\/j.msard.2021.103308_bib0006","first-page":"S7","article-title":"Analysis of current multiple sclerosis registries","volume":"76","author":"Hurwitz","year":"2011","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2021.103308_bib0050","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1474-4422(17)30007-8","article-title":"Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study","volume":"16","author":"Kalincik","year":"2017","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.msard.2021.103308_bib0040","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ana.21375","article-title":"Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study","volume":"63","author":"Khaleeli","year":"2008","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2021.103308_bib0042","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1212\/CPJ.0000000000000112","article-title":"Multiple sclerosis in US minority populations: clinical practice insights","volume":"5","author":"Khan","year":"2015","journal-title":"Neurol. Clin. Pract."},{"issue":"3","key":"10.1016\/j.msard.2021.103308_bib0044","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1212\/WNL.0b013e3181e8e72a","article-title":"Rapid disease course in African Americans with multiple sclerosis","volume":"75","author":"Kister","year":"2010","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2021.103308_bib0008","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/01376517-200106000-00009","article-title":"Problems reported by elderly patients with multiple sclerosis","volume":"33","author":"Klewer","year":"2001","journal-title":"J. Neurosci. Nurs."},{"issue":"9","key":"10.1016\/j.msard.2021.103308_bib0039","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/jnnp.2010.208173","article-title":"The natural history of secondary progressive multiple sclerosis","volume":"81","author":"Koch","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.msard.2021.103308_bib0014","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"issue":"24","key":"10.1016\/j.msard.2021.103308_bib0012","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1212\/WNL.0000000000009636","article-title":"The 2013 clinical course descriptors for multiple sclerosis: a clarification","volume":"94","author":"Lublin","year":"2020","journal-title":"Neurology"},{"issue":"16 Suppl","key":"10.1016\/j.msard.2021.103308_bib0002","first-page":"s294","article-title":"Multiple sclerosis update","volume":"19","author":"Markowitz","year":"2013","journal-title":"Am. J. Manag. Care"},{"issue":"3","key":"10.1016\/j.msard.2021.103308_bib0009","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1352458508099477","article-title":"The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated","volume":"15","author":"Marrie","year":"2009","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103308_bib0028","unstructured":"Milliman Client Report. Multiple sclerosis: new perspectives on the patient journey-update 2019 [Available from: http:\/\/www.milliman.com\/uploadedFiles\/insight\/2019\/MSPatient-Journey-2019.pdf]."},{"issue":"1","key":"10.1016\/j.msard.2021.103308_bib0013","first-page":"55","article-title":"Disability in elderly people with multiple sclerosis: an analysis of baseline data from the Sonya Slifka longitudinal multiple sclerosis study","volume":"19","author":"Minden","year":"2004","journal-title":"NeuroRehabilitation"},{"key":"10.1016\/j.msard.2021.103308_bib0034","unstructured":"National Multiple Sclerosis Society. Disease modifying agents for MS 2018 Available from: http:\/\/www.nationalmssociety.org\/NationalMSSociety\/media\/MSNationalFiles\/Brochures\/Brochure-The-MS-Disease-Modifying-Medications.pdf."},{"key":"10.1016\/j.msard.2021.103308_bib0060","unstructured":"Olek Michael J, M.E. Initial disease- modifing therapy for relapsing-remitting multiple sclerosis in adults. 2021 April 14, 2021 [cited 2021 May 1]; Available from: uptodate.com\/contents\/initial-disease-modifying-therapy-for-relapsing-remitting-multiple-sclerosis-in-adults#H2502924384."},{"key":"10.1016\/j.msard.2021.103308_bib0027","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.msard.2018.09.038","volume":"27","author":"Ontaneda","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"16 Suppl","key":"10.1016\/j.msard.2021.103308_bib0011","first-page":"s307","article-title":"Managed care aspects of managing multiple sclerosis","volume":"19","author":"Owens","year":"2013","journal-title":"Am. J. Manag. Care"},{"issue":"1","key":"10.1016\/j.msard.2021.103308_bib0033","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1212\/WNL.0000000000001094","article-title":"Relapses and disability accumulation in progressive multiple sclerosis","volume":"84","author":"Paz Sold\u00e1n","year":"2015","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.msard.2021.103308_bib0026","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med. Care"},{"issue":"6","key":"10.1016\/j.msard.2021.103308_bib0036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122686","article-title":"Male sex is independently associated with faster disability accumulation in relapse-onset ms but not in primary progressive MS","volume":"10","author":"Ribbons","year":"2015","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.msard.2021.103308_bib0054","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2021.103308_bib0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40120-018-0123-y","article-title":"Treatment patterns, healthcare resource utilization, and costs among medicare patients with multiple sclerosis in relation to disease-modifying therapy and corticosteroid treatment","volume":"8","author":"Sanchirico","year":"2019","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2021.103308_bib0015","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/451912","article-title":"Multiple sclerosis in older adults: the clinical profile and impact of interferon Beta treatment","volume":"2015","author":"Shirani","year":"2015","journal-title":"Biomed. Res. Int."},{"issue":"6","key":"10.1016\/j.msard.2021.103308_bib0030","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1046\/j.1468-1331.2002.00501.x","article-title":"Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis","volume":"9","author":"Sorensen","year":"2002","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2021.103308_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.17.00067","article-title":"Using a federated network of real-world data to optimize clinical trials operations","volume":"2","author":"Topaloglu","year":"2018","journal-title":"JCO Clin. Cancer Inform."},{"issue":"9","key":"10.1016\/j.msard.2021.103308_bib0049","article-title":"Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis","author":"Tramacere","year":"2015","journal-title":"Cochr. Database Syst. Rev."},{"issue":"12","key":"10.1016\/j.msard.2021.103308_bib0032","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/jnnp.2008.145805","article-title":"Relapses in multiple sclerosis are age- and time-dependent","volume":"79","author":"Tremlett","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.msard.2021.103308_bib0005","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41582-019-0183-3","article-title":"Epidemiology and treatment of multiple sclerosis in elderly populations","volume":"15","author":"Vaughn","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2021.103308_bib0053","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1177\/1352458513507821","article-title":"Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial","volume":"20","author":"Vermersch","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103308_bib0004","doi-asserted-by":"crossref","unstructured":"Wallin, M.T., et\u00a0al., The prevalence of MS in the United States. A population-based estimate using health claims data, 2019. 92(10): p. e1029\u2013e1040.","DOI":"10.1212\/WNL.0000000000007035"},{"key":"10.1016\/j.msard.2021.103308_bib0017","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3389\/fneur.2017.00577","article-title":"Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments","volume":"8","author":"Weideman","year":"2017","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2021.103308_bib0001","article-title":"Is multiple sclerosis an autoimmune disease?","volume":"2012","author":"Wootla","year":"2012","journal-title":"Autoimmun. Dis."},{"issue":"7","key":"10.1016\/j.msard.2021.103308_bib0064","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11910-020-01046-2","article-title":"Impact of age on multiple sclerosis disease activity and progression","volume":"20","author":"Zeydan","year":"2020","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.msard.2021.103308_bib0016","doi-asserted-by":"crossref","DOI":"10.1177\/1756286420969016","article-title":"Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials","volume":"13","author":"Zhang","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2021.103308_bib0022","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211006499","article-title":"Disease-modifying therapy prescription patterns in people with multiple sclerosis by age","volume":"14","author":"Zhang","year":"2021","journal-title":"Ther. Adv. Neurol. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821005757?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821005757?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T16:33:52Z","timestamp":1735576432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821005757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":64,"alternative-id":["S2211034821005757"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103308","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescribing of disease modifying agents in older adults with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103308","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103308"}}